CLINICAL PHARMACOLOGY and THERAPEUTICS

Editor

Walter Modell, M.D.

Editorial Board

Arthur J. Atkinson, Jr., M.D.
Frank M. Berger, M.D., D.Sc.
Karl H. Beyer, Jr., M.D., Ph.D.
Hylan A. Bickerman, M.D.
Edward A. Carr, Jr., M.D.
Leighton E. Cluff, M.D.
Allan H. Conney, Ph.D.
T. S. Danowski, M.D.
Peter G. Dayton, D.Sc.
Arthur C. DeGraff, M.D.
Peter Dineen, M.D.
Edward F. Domino, M.D.
Henry W. Elliott, M.D., Ph.D.†
Alvan R. Feinstein, M.D.
Max Fink, M.D.
Robert B. Forney, Ph.D.
Emil Frei, III, M.D.
Franz Gross, M.D.
Arthur Hull Hayes, Jr., M.D.
Leo E. Hollister, M.D.
Bartholomew P. Hsi, Ph.D.
Murray E. Jarvik, M.D.
Ernest Jawetz, M.D., Ph.D.
Stanley A. Kaplan, Ph.D.
Attallah Kappas, M.D.
Arthur S. Keats, M.D.
Richard H. Kessler, M.D.
Joseph B. Kirsner, M.D., Ph.D.
Kenneth G. Kohlstaedt, M.D.
Louis Lasagna, M.D.
Louis Lemberger, M.D., Ph.D.
Gerhard Levy, Pharm.D.
T. A. Loomis, M.D., Ph.D.
Daniel S. Lukas, M.D.
Fletcher H. McDowell, M.D.
Dean T. Mason, M.D.
Jerry R. Mitchell, M.D., Ph.D.
Arno G. Motulsky, M.D.
R. K. Richards, M.D.
David G. Shand, M.B., Ph.D.
Jay Tepperman, M.D.
Leroy D. Vandam, M.D.
Elliot S. Vesell, M.D.
John G. Wagner, Ph.D.
E. Leong Way, Ph.D.

†Deceased.

Volume 20, July-December, 1976
The C. V. Mosby Company, St. Louis

Volume 20
Copyright © 1976 by
The C. V. Mosby Company

All rights reserved

Printed in the United States of America

Index to volume 20

Author index

A

ABRAHAM, G. N. (*See* Brown et al.), 395
ABRAMS, W. B. Therapeutics and government: 1776 and 1976, 1
ACCHIARDO, S. (*See* Carter et al.), 565
ALVARES, A. P. (*See* Chang et al.), 219
—. (*See* Conney et al.), 633
—. (*See* Kappas et al.), 643
ANCH, A. M. (*See* Karacan et al.), 682
ANDERSON, K. E. (*See* Chang et al.), 219
—. (*See* Conney et al.), 633
—. (*See* Kappas et al.), 643
ASBURY, M. (*See* Ramsay et al.), 167
ATKINSON, A. J., JR., KRUMLOVSKY, F. A., HUANG, C. M., AND DEL GRECO, F. Hemodialysis for severe procainamide toxicity: Clinical and pharmacokinetic observations, 585

B

BACHUR, N. R. (*See* Chang et al.), 611
BAER-WEISS, V. (*See* Gritz et al.), 552
BAILAR, J. C. Clinical biostatistics. Bailar's laws of data analysis, 113
BALIAH, T. (*See* Levy et al.), 512
BARAK, A. J. (*See* Sorell et al.), 365
BARDEN, T. P. (*See* Bloomfield et al.), 499
BATES, T. R. (*See* Rosenberg and Bates), 227
BENET, L. Z. (*See* Galeazzi et al.), 278
BENNETT, E. P. (*See* Johnsen et al.), 233
BIGGS, J. T. (*See* Ziegler et al.), 458
BIRCHER, J., KÜPFER, A., GIKALOV, I., AND PREISIG, R. Aminopyrine demethylation measured by breath analysis in cirrhosis, 484
BIXLER, E. O. (*See* Kales et al.), 541
BLASCHKE, T. F. (*See* Williams et al.), 90, 290
BLAUG, S. M. (*See* Juhl et al.), 387
BLOOMFIELD, S. S., BARDEN, T. P., AND MITCHELL, J. Aspirin and codeine in two postpartum pain models, 499
BODEY, G. P. (*See* Grose et al.), 579
BODINE, J. A., STRAUSBAUGH, L. J., AND SANDE, M. A. Ampicillin and an ester in experimental *Hemophilus influenzae* meningitis, 727
BOLLI, P., WOOD, A. J., AND SIMPSON, F. O. Effects of prazosin in patients with hypertension, 138
BOOTH, G. H. (*See* Karacan et al.), 682
BORGÅ, O., ODAR-CEDERLÖF, I., RINGBERGER, V.-A., AND NORLIN, A. Protein binding of salicylate in uremic and normal plasma, 464
—. (*See* Odar-Cederlöf and Borgå), 36
BRANCH, R. A., JAMES, J. A., AND READ, A. E. The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic liver disease, 81
BRESSLER, R. (*See* Marcus et al.), 253
BRIGGS, W. (*See* Reidenberg et al.), 67
BRIGGS, W. A. (*See* Gibson et al.), 720
BROOKS, M. A. (*See* Dixon et al.), 450
BROWN, D. D., DORMOIS, J. C., ABRAHAM, G. N., LEWIS, K., AND DIXON, K. Effect of furosemide on the renal excretion of digoxin, 395
—. (*See* Juhl et al.), 387
BROWN, H. C., CARRUTHERS, S. G., JOHNSTON, G. D., KELLY, J. G., MCAINSH, J., MCDEVITT, D. G., AND SHANKS, R. G. Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker, 524
BULPITT, C. J. (*See* Fraser et al.), 369
BURNETT, D. A. (*See* Sorell et al.), 365

C

CANALE, V. (*See* Rifkind et al.), 476
CARRIÈRE, S., DANDAVINO, R., ROCHEFORT, F., DAIGNEAULT, A., AND LANOIX, C. Bumetanide, a new loop diuretic, 424
CARRUTHERS, S. G. (*See* Brown et al.), 524
CARSON, P., AND TRENHOLME, G. M., 743 (Correspondence)

July, pp. 1-124; August, pp. 125-252; September, pp. 253-378; October, pp. 379-506; November, pp. 507-632; December, pp. 633-762.

CARTER, R., HEERDT, M., AND ACCHIARDO, S. Fluoride kinetics after enflurane anesthesia in healthy and anephric patients and in patients with poor renal function, 565
CARUSO, F. S. (*See* Gilbert et al.), 359
CHANG, P., RIGGS, C. E., JR., SCHEERER, M. T., WIERNIK, P. H., AND BACHUR, N. R. Combination chemotherapy with adriamycin and streptozotocin. II. Clinicopharmacologic correlation of augmented adriamycin toxicity caused by streptozotocin, 611
— AND WIERNIK, P. H. Combination chemotherapy with adriamycin and streptozotocin. I. Clinical results in patients with advanced sarcoma, 605
CHANG, R. L., WOOD, A. W., DIXON, W. R., CONNEY, A. H., ANDERSON, K. E., EISEMAN, J., AND ALVARES, A. P. Antipyrine: Radioimmunoassay in plasma and saliva following administration of a high dose and a low dose, 219
CHAPLIN, M. D. (*See* Runkel et al.), 269
CHENG, F. H. (*See* Juhl et al.), 387
CHILD, C., NOLAN, G., AND JUBIZ, W. Changes in serum thyroxine, triiodothyronine, and thyrotropin induced by lithium in normal subjects and in rats, 715
CLAYTON, P. J. (*See* Ziegler et al.), 458
CO, B. T. (*See* Ziegler et al.), 458
COHEN, A. Intestinal blood loss after a new anti-inflammatory drug, sulindac, 238
COLDING, H. (*See* Sardemann et al.), 59
COLLSTE, P. (*See* von Bahr et al.), 130
CONNEY, A. H., PANTUCK, E. J., HSIAO, K.-C., GARLAND, W. A., ANDERSON, K. E., ALVARES, A. P., AND KAPPAS, A. Enhanced phenacetin metabolism in human subjects fed charcoal-broiled beef, 633
—. (*See* Chang et al.), 219
—. (*See* Fink et al.), 184
—. (*See* Kapitulnik et al.), 557
—. (*See* Kappas et al.), 643
COOK, D. R., WINGARD, L. B., JR., AND TAYLOR, F. H. Pharmacokinetics of succinylcholine in infants, children, and adults, 493
COOPER, S. A., AND BEAVER, W. T. A model to evaluate mild analgesics in oral surgery outpatients, 241
COOPER, S. D. (*See* Sellers et al.), 199

D

DAIGNEAULT, A. (*See* Carrière et al.), 424
DALTON, W. S., MARTZ, R., RODDA, B. E., LEMBERGER, L., AND FORNEY, R. B. Influence of cannabidiol on secobarbital effects and plasma kinetics, 695
DANDAVINO, R. (*See* Carrière et al.), 424
DEL GRECO, F. (*See* Atkinson et al.), 585
DESAGER, J.-P. (*See* Harvengt and Desager), 310
DICKERSON, J. (*See* Marcus et al.), 253
DISANTO, A. R. (*See* Novak et al.), 109
DIXON, K. (*See* Brown et al.), 395
DIXON, R., BROOKS, M. A., POSTMA, E., HACKMAN, M. R., SPECTOR, S., MOORE, J. D., AND SCHWARTZ, M. A. N-Desmethyldiazepam: A new metabolite of chlordiazepoxide in man, 450
DIXON, W. R. (*See* Chang et al.), 219
DOLLERY, C. T. (*See* Follath et al.), 24
—. (*See* Fraser et al.), 369
DORMOIS, J. C. (*See* Brown et al.), 395
DUNKERLEY, R., JOHNSON, R., SCHENKER, S., AND WILKINSON, G. R. Gastric and biliary excretion of meperidine in man, 546
DZINDZIO, B. S. (*See* Ueda et al.), 260

E

EISEMAN, J. (*See* Chang et al.), 219
ENDRENYI, L., INABA, T., AND KALOW, W. Genetic study of amobarbital elimination based on its kinetics in twins, 701
—. (*See* Inaba et al.), 439
EVANS, M. A., MARTZ, R., RODDA, B. E., LEMBERGER, L., AND FORNEY, R. B. Effects of marihuana-dextroamphetamine combination, 350

F

FEINSTEIN, A. R. Clinical biostatistics. XXXVII. Demeaned errors, confidence games, nonplussed minuses, inefficient coefficients, and other statistical disruptions of scientific communication, 617
FELDMAN, J. M., AND ROCHE, J. Effect of oral contraceptives on platelet monoamine oxidase, monoamine excretion, and adrenocortical function, 670
FINK, M., IRWIN, P., WEINFELD, R. E., SCHWARTZ, M. A., AND CONNEY, A. H. Blood levels and electroencephalographic effects of diazepam and bromazepam, 184
FIORENTINI, C. (*See* Guazzi et al.), 304
FLECKENSTEIN, L. (*See* Joubert et al.), 676
FOLLATH, F., KERSTING, F., LEWIS, G. R. J., WALDEN, R. J., WOOLHOUSE, N. M., AND DOLLERY, C. T. Cardiovascular effects of a new inotropic drug in dog and normal man, 24
FORNEY, R. B. (*See* Dalton et al.), 695
—. (*See* Evans et al.), 350
FRANKE, K. (*See* Stanski et al.), 571
FRASER, H. S., BULPITT, C. J., KAHN, C., MOULD, G., MUCKLOW, J. C., AND DOLLERY, C. T. Factors affecting antipyrine metabolism in West African villagers, 369
FRISK-HOLMBERG, M. (*See* McDevitt et al.), 152
—. (*See* von Bahr et al.), 130

G

GALEAZZI, R. L., BENET, L. Z., AND SHEINER, L. B. Relationship between the pharmacokinetics and pharmacodynamics of procainamide, 278
GALLARDO, E. (*See* Velasco et al.), 31
GARLAND, W. A. (*See* Conney et al.), 633
GASPARO, M. (*See* Reidenberg et al.), 67
GIBSON, T. P., MATUSIK, E., NELSON, L. D., AND BRIGGS, W. A. Artificial kidneys and clearance calculations, 720
GIKALOV, I. (*See* Bircher et al.), 484
GILBERT, M. S., HANOVER, R. M., MOYLAN, D. S., AND CARUSO, F. S. Intramuscular butorphanol and meperidine in postoperative pain, 359
GILBERTSON, T. J. (*See* Novak et al.), 109
GILFRICH, H.-J. (*See* Jähnchen et al.), 342
GOLDSTEIN, A. (*See* Judson et al.), 445
GOULET, J. R., KINKEL, A. W., AND SMITH, T. C. Metabolism of ethosuximide, 213
GREENBLATT, D. J., SCHILLINGS, R. T., KYRIAKOPOULOS, A. A., SHADER, R. I., SISENWINE, S. F., KNOWLES, J. A., AND RUELIUS, H. W. Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral ^{14}C-lorazepam, 329
—. (*See* Stanski et al.), 571
GRITZ, E. R., BAER-WEISS, V., AND JARVIK, M. E. Titration of nicotine intake with full-length and half-length cigarettes, 552
GROSE, W. E., BODEY, G. P., AND STEWART, D. Observations in man on some pharmacologic features of cefamandole, 579
GROTH, U. (*See* Jähnchen et al.), 342
GUAZZI, M., FIORENTINI, C., POLESE, A., OLIVARI, M. T., AND MAGRINI, F. Antihypertensive action of propranolol in man: Lack of evidence for a neural depressive effect, 304
GUEVARA, J. (*See* Velasco et al.), 31
GUILLORY, J. K. (*See* Juhl et al.), 387

H

HACKMAN, M. R. (*See* Dixon et al.), 450
HAGLUND, K. (*See* von Bahr et al.), 130
HANOVER, R. M. (*See* Gilbert et al.), 359
HARRISON, I. (*See* Ramsay et al.), 167
HARVENGT, C., AND DESAGER, J.-P. Colestipol in familial type II hyperlipoproteinemia: A three-year trial, 310
HASSAR, M., AND WEINTRAUB, M. "Uninformed" consent and the wealthy volunteer: An analysis of patient volunteers in a clinical trial of a new anti-inflammatory drug, 379 (Commentary)
HAURI, P. (*See* Kales et al.), 541
HEANEY, R. P., AND SAVILLE, P. D. Etidronate disodium in postmenopausal osteoporosis, 593
HEERDT, M. (*See* Carter et al.), 565
HENDEL, J. (*See* Sardemann et al.), 59
HEPNER, G. W., AND VESELL, E. S. Aminopyrine disposition: Studies on breath, saliva, and urine of normal subjects and patients with liver disease, 654
—. (*See* Vesell et al.), 661
HERNANDEZ, A. (*See* Materson et al.), 142
HÖJER, B. (*See* Wilson et al.), 48
HOLLIFIELD, J. W. (*See* McDevitt et al.), 152
HORNING, M. G. (*See* Kellermann et al.), 72
HORNS, W. H. (*See* Judson et al.), 445
HSIAO, K.-C. (*See* Conney et al.), 633
HUANG, C. M. (*See* Atkinson et al.), 585
HUDSON, L. D. (*See* Lakshminarayan et al.), 178
HVIDBERG, E. F. (*See* Sardemann et al.), 59
HYDE, J. S., YAMSHON, D., ISENBERG, P. D., AND SCHUR, S. Metaproterenol in children with chronic asthma, 207

I

INABA, T., TANG, B. K., ENDRENYI, L., AND KALOW, W. Amobarbital—a probe of hepatic drug oxidation in man, 439
—. (*See* Endrenyi et al.), 701
IRWIN, P. (*See* Fink et al.), 184
ISENBERG, P. D. (*See* Hyde et al.), 207

J

JÄHNCHEN, E., MEINERTZ, T., GILFRICH, H.-J., GROTH, U., AND MARTINI, A. The enantiomers of phenprocoumon: Pharmacodynamic and pharmacokinetic studies, 342
JAMES, J. A. (*See* Branch et al.), 81
JANSSEN, H. (*See* Storstein and Janssen), 15
JARVIK, M. E. (*See* Gritz et al.), 552
JERINA, D. M. (*See* Kapitulnik et al.), 557
JOHNSEN, S. G., KAMPMANN, J. P., BENNETT, E. P., AND JØRGENSEN, F. S. Enzyme induction by oral testosterone, 233
JOHNSON, R. (*See* Dunkerley et al.), 546
JOHNSTON, G. D. (*See* Brown et al.), 524
JORFELT, L. (*See* von Bahr et al.), 130
JØRGENSEN, F. S. (*See* Johnsen et al.), 233
JOUBERT, P., KROENING, B., WEINTRAUB, M., AND FLECKENSTEIN, L. Correlation between electrocardiographic changes, serum digoxin, and total body digoxin content, 676
JUBIZ, W. (*See* Child et al.), 715
JUDSON, B. A., HORNS, W. H., AND GOLDSTEIN, A. Side effects of levomethadone and racemic methadone in a maintenance program, 445
JUHL, R. P., SUMMERS, R. W., GUILLORY, J. K., BLAUG, S. M., CHENG, F. H., AND BROWN, D. D. Effect of sulfasalazine on digoxin bioavailability, 387

K

KAHN, C. (*See* Fraser et al.), 369

KALES, A., HAURI, P., BIXLER, E. O., AND SILBERFARB, P. Effectiveness of intermediate-term use of secobarbital, 541
KALOW, W. (*See* Endrenyi et al.), 701
—. (*See* Inaba et al.), 439
KAMPMANN, J. P. (*See* Johnsen et al.), 233
—. (*See* Sardemann et al.), 59
KAPITULNIK, J., LEVIN, W., POPPERS, P. J., TOMASZEWSKI, J. E., JERINA, D. M., AND CONNEY, A. H. Comparison of the hydroxylation of zoxazolamine and benzo[a]pyrene in human placenta: Effect of cigarette smoking, 557
KAPPAS, A., ANDERSON, K. E., CONNEY, A. H., AND ALVARES, A. P. Effects of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man, 643
—. (*See* Conney et al.), 633
KARACAN, I., THORNBY, J. I., ANCH, A. M., BOOTH, G. H., WILLIAMS, R. L., AND SALIS, P. J. Dose-related sleep disturbances induced by coffee and caffeine, 682
KELLERMANN, G., LUYTEN-KELLERMANN, M., HORNING, M. G., AND STAFFORD, M. Elimination of antipyrine and benzo[a]pyrene metabolism in cultured human lymphocytes, 72
KELLY, J. G. (*See* Brown et al.), 524
KERSTING, F. (*See* Follath et al.), 24
KINKEL, A. (*See* Smith and Kinkel), 738
KINKEL, A. W. (*See* Goulet et al.), 213
KNOWLES, J. A. (*See* Greenblatt et al.), 329
KOCH-WESER, J. (*See* Stanski et al.), 571
KROENING, B. (*See* Joubert et al.), 676
KRUMLOVSKY, F. A. (*See* Atkinson et al.), 585
KÜPFER, A. (*See* Bircher et al.), 484
KYRIAKOPOULOS, A. A. (*See* Greenblatt et al.), 329

L

LAKSHMINARAYAN, S., SAHN, S. A., HUDSON, L. D., AND WEIL, J. V. Effect of diazepam on ventilatory responses, 178
LANOIX, C. (*See* Carrière et al.), 424
LASAGNA, L. Drug discovery and introduction: Regulation and overregulation, 507 (Commentary)
LEMBERGER, L. (*See* Dalton et al.), 695
—. (*See* Evans et al.), 350
LEVIN, W. (*See* Kapitulnik et al.), 557
LEVY, G., BALIAH, T., AND PROCKNAL, J. A. Effect of renal transplantation on protein binding of drugs in serum of donor and recipient, 512
—. (*See* Yacobi et al.), 300
LEWIS, G. R. J. (*See* Follath et al.), 24
LEWIS, K. (*See* Brown et al.), 395
LOWENTHAL, D. T. (*See* Reidenberg et al.), 67
LUYTEN-KELLERMANN, M. (*See* Kellermann et al.), 72

M

MAGRINI, F. (*See* Guazzi et al.), 304
MANNINEN, V., REISSELL, P., AND PAUKKALA, E. Transient cardiac arrhythmias after single daily maintenance doses of digoxin, 266
MARCUS, F. I., DICKERSON, J., PIPPIN, S., STAFFORD, M., AND BRESSLER, R. Digoxin bioavailability: Formulations and rates of infusions, 253
MARTIN, W. R. (*See* McClane and Martin), 192
MARTINI, A. (*See* Jähnchen et al.), 342
MARTZ, R. (*See* Dalton et al.), 695
—. (*See* Evans et al.), 350
MASON, D. T. (*See* Salel et al.), 690
MASON, W. D., AND WINER, N. Pharmacokinetics of oxprenolol in normal subjects, 401
MATERSON, B. J., MICHAEL, U. F., OSTER, J. R., AND PEREZ-STABLE, E. C. Antihypertensive effects of oxprenolol and propranolol, 142
MATHER, L. E., AND TUCKER, G. T. Systemic availability of orally administered meperidine, 535
MATTIE, H. (*See* Nauta and Mattie), 98
MATUSIK, E. (*See* Gibson et al.), 720
MCAINSH, J. (*See* Brown et al.), 524
MCALLISTER, R. G., JR. Intravenous propranolol administration: A method for rapidly achieving and sustaining desired plasma levels, 517
MCCLANE, T. K., AND MARTIN, W. R. Subjective and physiologic effects of morphine, pentobarbital, and meprobamate, 192
MCCULLOUGH, W. (*See* McLeod et al.), 733
MCDEVITT, D. G., FRISK-HOLMBERG, M., HOLIFIELD, J. W., AND SHAND, D. G. Plasma binding and the affinity of propranolol for a beta receptor in man, 152
—. (*See* Brown et al.), 524
MCLEOD, P. J., WRIGHT, J. M., AND MCCULLOUGH, W. Antihypertensive efficacy of a single bedtime dose of methyldopa, 733
MEFFIN, P. J. (*See* Williams et al.), 90, 290
MEINERTZ, T. (*See* Jähnchen et al.), 342
MELMON, K. L. The clinical pharmacologist and scientifically unsound regulations for drug development, 125 (Editorial)
—. (*See* Williams et al.), 90, 290
MICHAEL, U. F. (*See* Materson et al.), 142
MITCHELL, J. (*See* Bloomfield et al.), 499
MOORE, J. D. (*See* Dixon et al.), 450
MORRISON, G. (*See* Rudnick et al.), 413
MOULD, G. (*See* Fraser et al.), 369
MOYLAN, D. S. (*See* Gilbert et al.), 359
MUCKLOW, J. C. (*See* Fraser et al.), 369
MULÉ, S. J. (*See* Verebey et al.), 315

N

NAUTA, E. H., AND MATTIE, H. Dicloxacillin and cloxacillin: Pharmacokinetics in healthy and hemodialysis subjects, 98
NELSON, L. D. (*See* Gibson et al.), 720
NEW, M. I. (*See* Rifkind et al.), 476
NOLAN, G. (*See* Child et al.), 715
NORLIN, A. (*See* Borgå et al.), 464
NOVAK, E., GILBERTSON, T. J., SECKMAN, C. E., STEWART, R. D., DISANTO, A. R., AND STUBBS, S. S. Anorectal pruritus after intravenous hydrocortisone sodium succinate and sodium phosphate, 109

O

ODAR-CEDERLÖF, I., AND BORGÅ, O. Impaired plasma protein binding of phenytoin in uremia and displacement effect of salicylic acid, 36
—. (*See* Borgå et al.), 464
OLIVARI, M. T. (*See* Guazzi et al.), 304
ORME, M. (*See* von Bahr et al.), 130
ORTEGA, E. (*See* Runkel et al.), 269
OSTER, J. R. (*See* Materson et al.), 142
ÖSTMAN, J. (*See* von Bahr et al.), 130

P

PANTUCK, E. J. (*See* Conney et al.), 633
PASSANANTI, G. T. (*See* Vesell et al.), 661
PAUKKALA, E. (*See* Manninen et al.), 266
PEREZ-STABLE, E. C. (*See* Materson et al.), 142
PIPPIN, S. (*See* Marcus et al.), 253
PLAJA, J. (*See* Velasco et al.), 31
POLESE, A. (*See* Guazzi et al.), 304
POPPERS, P. J. (*See* Kapitulnik et al.), 557
POSTMA, E. (*See* Dixon et al.), 450
PREISIG, R. (*See* Bircher et al.), 484
PRICE, J. (*See* Salel et al.), 690
PROCKNAL, J. A. (*See* Levy et al.), 512

R

RAMSAY, L., SHELTON, J., HARRISON, I., TIDD, M., AND ASBURY, M. Spironolactone and potassium canrenoate in normal man, 167
RANE, A. (*See* Wilson et al.), 48
READ, A. E. (*See* Branch et al.), 81
REIDENBERG, M. M., LOWENTHAL, D. T., BRIGGS, W., AND GASPARO, M. Pentobarbital elimination in patients with poor renal function, 67
REISSELL, P. (*See* Manninen et al.), 266
RESNICK, R. B. (*See* Verebey et al.), 315
RIFKIND, A. B., CANALE, V., AND NEW, M. I. Antipyrine clearance in homozygous β-thalassemia, 476
RIGGS, C. E., JR. (*See* Chang et al.), 611
RINGBERGER, V.-A. (*See* Borgå et al.), 464
ROCHE, J. (*See* Feldman and Roche), 670
ROCHEFORT, F. (*See* Carrière et al.), 424
RODDA, B. E. (*See* Dalton et al.), 695
—. (*See* Evans et al.), 350
ROSENBERG, H. A., AND BATES, T. R. The influence of food on nitrofurantoin bioavailability, 227
ROWLAND, M. (*See* Williams et al.), 90, 290
RUDNICK, M., MORRISON, G., WALKER, B., AND SINGER, I. Renal failure, hemodialysis, and nafcillin kinetics, 413
RUELIUS, H. W. (*See* Greenblatt et al.), 329
RUNKEL, R., CHAPLIN, M. D., SEVELIUS, H., ORTEGA, E., AND SEGRE, E. Pharmacokinetics of naproxen overdoses, 269

S

SAHN, S. A. (*See* Lakshminarayan et al.), 178
SALEL, A. F., ZELIS, R., SODHI, H. S., PRICE, J., AND MASON, D. T. Probucol: A new cholesterol-lowering drug effective in patients with type II hyperlipoproteinemia, 690
SALIS, P. J. (*See* Karacan et al.), 682
SANDE, M. A. (*See* Bodine et al.), 727
SARDEMANN, H., COLDING, H., HENDEL, J., KAMPMANN, J. P., HVIDBERG, E. F., AND VEJLSGAARD, R. Kinetics and dose calculations of amikacin in the newborn, 59
SAVILLE, P. D. (*See* Heaney and Saville), 593
SCHARY, W. L. (*See* Williams et al.), 90
SCHEERER, M. T. (*See* Chang et al.), 611
SCHENKER, S. (*See* Dunkerley et al.), 546
SCHILLINGS, R. T. (*See* Greenblatt et al.), 329
SCHUR, S. (*See* Hyde et al.), 207
SCHWARTZ, M. A. (*See* Dixon et al.), 450
—. (*See* Fink et al.), 184
SECKMAN, C. E. (*See* Novak et al.), 109
SEGRE, E. (*See* Runkel et al.), 269
SELLERS, E. M., COOPER, S. D., ZILM, D. H., AND SHANKS, C. Lithium treatment during alcoholic withdrawal, 199
SELWYN, A. (*See* Stanski et al.), 571
SEVELIUS, H. (*See* Runkel et al.), 269
SHADER, R. I. (*See* Greenblatt et al.), 329
—. (*See* Stanski et al.), 571
SHAND, D. G. (*See* McDevitt et al.), 152
SHANKS, C. (*See* Sellers et al.), 199
—. (*See* Brown et al.), 524
SHEINER, L. B. (*See* Galeazzi et al.), 278
SHELTON, J. (*See* Ramsay et al.), 167
SILBERFARB, P. (*See* Kales et al.), 541
SIMPSON, F. O. (*See* Bolli et al.), 138
SINGER, I. (*See* Rudnick et al.), 413
SISENWINE, S. F. (*See* Greenblatt et al.), 329
SJÖQVIST, F. (*See* von Bahr et al.), 130
SMITH, M. (*See* Materson et al.), 142
SMITH, T. C., AND KINKEL, A. Absorption and metabolism of phenytoin from tablets and capsules, 738
—. (*See* Goulet et al.), 213

SODHI, H. S. (*See* Salel et al.), 690
SORRELL, M. F., BURNETT, D. A., TUMA, D. J., AND BARAK, A. J. Paradoxical urinary excretion of D-glucaric acid in acute viral hepatitis, 365
SPECTOR, S. (*See* Dixon et al.), 450
STAFFORD, M. (*See* Kellermann et al.), 72
—. (*See* Marcus et al.), 253
STANSKI, D. R., GREENBLATT, D. J., SELWYN, A., SHADER, R. I., FRANKE, K., AND KOCH-WESER, J. Plasma and cerebrospinal fluid concentrations of chlordiazepoxide and its metabolites in surgical patients, 571
STEWART, D. (*See* Grose et al.), 579
STEWART, R. D. (*See* Novak et al.), 109
STORSTEIN, L. Studies on digitalis. V. The influence of impaired renal function, hemodialysis, and drug interaction on serum protein binding of digitoxin and digoxin, 6
—. AND JANSSEN, H. Studies on digitalis. VI. The effect of heparin on serum protein binding of digitoxin and digoxin, 15
—. Studies on digitalis. VII. Influence of nephrotic syndrome on protein binding, pharmacokinetics, and renal excretion of digitoxin and cardioactive metabolites, 158
STRAUSBAUGH, L. J. (*See* Bodine et al.), 727
STUBBS, S. S. (*See* Novak et al.), 109
SUMMERS, R. W. (*See* Juhl et al.), 387

T

TANG, B. K. (*See* Inaba et al.), 439
TAYLOR, F. H. (*See* Cook et al.), 493
TAYLOR, J. R. (*See* Ziegler et al.), 458
THORNBY, J. I. (*See* Karacan et al.), 682
TIDD, M. (*See* Ramsay et al.), 167
TOMASZEWSKI, J. E. (*See* Kapitulnik et al.), 557
TUCKER, G. T. (*See* Mather and Tucker), 535
TUMA, D. J. (*See* Sorell et al.), 365

U

UDALL, J. X. (*See* Yacobi et al.), 300
UEDA, C. T., WILLIAMSON, B. J., AND DZINDZIO, B. S. Absolute quinidine bioavailability, 260

V

VEJLSGAARD, R. (*See* Sardemann et al.), 59
VELASCO, M., GALLARDO, E., PLAJA, J., AND GUEVERA, J. A sliding intravenous dose schedule for clonidine in hypertensive patients, 31
VEREBEY, K., VOLAVKA, J., MULÉ, S. J., AND RESNICK, R. B. Naltrexone: Disposition, metabolism, and effects after acute and chronic dosing, 315
VESELL, E. S., PASSANANTI, G. T., AND HEPNER, G. W. Interaction between antipyrine and aminopyrine, 661
—. (*See* Hepner and Vesell), 654
VOLAVKA, J. (*See* Verebey et al.), 315
VON BAHR, C., COLLSTE, P., FRISK-HOLMBERG, M., HAGLUND, K., JORFELT, L., ORME, M., ÖSTMAN, J., AND SJÖQVIST, F. Plasma levels and effects of metoprolol on blood pressure, adrenergic beta receptor blockade, and plasma renin activity in essential hypertension, 130

W

WALDEN, R. J. (*See* Follath et al.), 24
WALKER, B. (*See* Rudnick et al.), 413
WEIL, J. V. (*See* Lakshminarayan et al.), 178
WEINFELD, R. E. (*See* Fink et al.), 184
WEINTRAUB, M. (*See* Hassar and Weintraub), 379 (Commentary)
—. (*See* Joubert et al.), 676
WIERNIK, P. H. (*See* Chang and Wiernik), 605
—. (*See* Chang et al.), 611
WILKINSON, G. R. (*See* Dunkerley et al.), 546
WILLIAMS, R. L., BLASCHKE, T. F., MEFFIN, P. J., MELMON, K. L., AND ROWLAND, M. Influence of viral hepatitis on the disposition of two compounds with high hepatic clearance: Lidocaine and indocyanine green, 290
—, SCHARY, W. L., BLASCHKE, T. F., MEFFIN, P. J., MELMON, K. L., AND ROWLAND, M. Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin, 90
—. (*See* Karacan et al.), 682
WILLIAMSON, B. J. (*See* Ueda et al.), 260
WILSON, J. T., HÖJER, B., AND RANE, A. Loading and conventional dose therapy with phenytoin in children: Kinetic profile of parent drug and main metabolite in plasma, 48
WINER, N. (*See* Mason and Winer), 401
WINGARD, L. B., JR. (*See* Cook et al.), 493
WOOD, A. J. (*See* Bolli et al.), 138
WOOD, A. W. (*See* Chang et al.), 219
WOOLHOUSE, N. M. (*See* Follath et al.), 24
WRIGHT, J. M. (*See* McLeod et al.), 733

Y

YACOBI, A., UDALL, J. A., AND LEVY, G. Intrasubject variation of warfarin binding to protein in serum of patients with cardiovascular disease, 300
YAMSHON, D. (*See* Hyde et al.), 207

Z

ZELIS, R. (*See* Salel et al.), 690
ZIEGLER, V. E., CLAYTON, P. J., TAYLOR, J. R., CO, B. T., AND BIGGS, J. T. Nortriptyline plasma levels and therapeutic response, 458
ZILM, D. H. (*See* Sellers et al.), 199

Subject index

A

Absorption and metabolism of phenytoin from tablets and capsules (Smith and Kinkel), 738

Adrenergic beta receptor blockade, blood pressure, and plasma renin activity in essential hypertension, plasma levels and effects of metoprolol on (von Bahr et al.), 130

Adrenoceptor blocker, beta-, clinical pharmacologic observations on atenolol (Brown et al.), 524

Adrenocortical function, platelet monoamine oxidase, monoamine excretion, and, effect of oral contraceptives on (Feldman and Roche), 670

Adriamycin and streptozotocin, combination chemotherapy with; clinical results in patients with advanced sarcoma (Chang et al.), 605

clinicopharmacologic correlation of augmented adriamycin toxicity caused by streptozotocin (Chang et al.), 611

Adults, infants, children, and, pharmacokinetics of succinylcholine in (Cook et al.), 493

Alcoholic withdrawal, lithium treatment during (Sellers et al.), 199

Aldosterone antagonist, potassium canrenoate approximately one-third as potent as spironolactone (Ramsay et al.), 167

American Society for Clinical Pharmacology and Therapeutics, 124, 251 (Announcement)

news, 632

notes of, 377, 504, 743

Amikacin in newborn, kinetics and dose calculations of (Sardemann et al.), 59

Aminopyrine, antipyrine and, interaction between (Vesell et al.), 661

demethylation measured by breath analysis in cirrhosis (Bircher et al.), 484

disposition: studies on breath, saliva, and urine of normal subjects and patients with liver disease (Hepner and Vesell), 654

Amobarbital elimination, genetic study of, based on its kinetics in twins (Endrenyi et al.), 701

Amobarbital—cont'd

probe of hepatic drug oxidation in man (Inaba et al.), 439

Ampicillin and ester in experimental *Hemophilus influenzae* meningitis (Bodine et al.), 727

Analgesic(s), codeine more selective than aspirin in postpartum pain (Bloomfield et al.), 499

mild, model to evaluate, in oral surgery outpatients (Cooper and Beaver), 241

Anephric patients, healthy and, and patients with poor renal function, fluoride kinetics after enflurane anesthesia in (Carter et al.), 565

Anesthesia, enflurane, fluoride kinetics after, in healthy and anephric patients and in patients with poor renal function (Carter et al.), 565

Announcements, 124, 251

Anorectal pruritus after intravenous hydrocortisone sodium succinate and sodium phosphate (Novak et al.), 109

Antagonists, other beta adrenergic, data on kinetic differences between oxprenolol and (Mason and Winer), 401

Antipyrine and aminopyrine, interaction between (Vesell et al.), 661

and benzo[a]pyrene metabolism in cultured human lymphocytes, elimination of (Kellermann et al.), 72

clearance in homozygous β-thalassemia (Rifkind et al.), 476

and indocyanine green, clearance of, in normal subjects and in patients with chronic liver disease (Branch et al.), 81

metabolism, factors affecting, in West African villagers (Fraser et al.), 369

radioimmunoassay in plasma and saliva following administration of high dose and low dose (Chang et al.), 219

and theophylline metabolism in man, effects of dietary protein and carbohydrate on (Kappas et al.), 643

Arrhythmias, transient cardiac, after single daily maintenance doses of digoxin (Manninen et al.), 266

July, pp. 1-124; August, pp. 125-252; September, pp. 253-378; October, pp. 379-506; November, pp. 507-632; December, pp. 633-762.

Aspirin and codeine in two postpartum pain models (Bloomfield et al.), 499
Asthma, chronic, metaproterenol in children with (Hyde et al.), 207
Atenolol, beta-adrenoceptor blocker, clinical pharmacologic observations on (Brown et al.), 524

B

Bailar's laws of data analysis (Bailar), 113 (Clinical biostatistics)
Bedtime dose, single, of methyldopa, antihypertensive efficacy of (McLeod et al.), 733
Beef, charcoal-broiled, enhanced phenacetin metabolism in human subjects fed (Conney et al.), 633
Benzo[a]pyrene metabolism, antipyrine and, elimination of, in cultured human lymphocytes (Kellermann et al.), 72
zoxazolamine and, in human placenta, comparison of hydroxylation of: effect of cigarette smoking (Kapitulnik et al.), 557
Biliary excretion, gastric and, of meperidine in man (Dunkerley et al.), 546
Bioavailability, absolute quinidine (Ueda et al.), 260
digoxin, effect of sulfasalazine on (Juhl et al.), 387
formulations and rates of infusions (Marcus et al.), 253
nitrofurantoin, influence of food on (Rosenberg and Bates), 227
Biochemical change, physiologic or, not detected in lithium treatment during alcoholic withdrawal (Sellers et al.), 199
Biostatistics, clinical. Bailar's laws of data analysis (Bailar), 113
XXXVII. Demeaned errors, confidence games, nonplussed minuses, inefficient coefficients, and other statistical disruptions of scientific communication (Feinstein), 617
Blood levels and electroencephalographic effects of diazepam and bromazepam (Fink et al.), 184
loss, intestinal, after new anti-inflammatory drug, sulindac (Cohen), 238
pressure, adrenergic beta receptor blockade, and plasma renin activity in essential hypertension, plasma levels and effects of metoprolol on (von Bahr et al.), 130
Books received, 252, 506, 744
Breath analysis in cirrhosis, aminopyrine demethylation measured by (Bircher et al.), 484
saliva, and urine of normal subjects and patients with liver disease, studies on; aminopyrine disposition (Hepner and Vesell), 654
Bromazepam, diazepam and, blood levels and electroencephalographic effects of (Fink et al.), 184
β-thalassemia, homozygous, antipyrine clearance in (Rifkind et al.), 476
Bumetanide, new loop diuretic (Carrière and Dandavino), 424
Butorphanol, intramuscular, and meperidine in postoperative pain (Gilbert et al.), 359

C

Caffeine, coffee and, dose-related sleep disturbances induced by (Karacan et al.), 682
Cannabidiol, influence of, on secobarbital effects and plasma kinetics (Dalton et al.), 695
Canrenoate, potassium, spironolactone and, in normal man (Ramsay et al.), 167
Carbohydrate, dietary protein and, effects of, on antipyrine and theophylline metabolism in man (Kappas et al.), 643
Cardiac arrhythmias, transient, after single daily maintenance doses of digoxin (Manninen et al.), 266
rate accelerated by use of prazosin in patients with hypertension (Bolli et al.), 138
Cardioactive metabolites, influence of nephrotic syndrome on protein binding, pharmacokinetics, and renal excretion of; studies on digitalis (Storstein), 158
Cardiovascular disease, intrasubject variation of warfarin binding to protein in serum of patients with (Yacobi et al.), 300
effects of new inotropic drug in dog and normal man (Follath et al.), 24
Cefamandole, some pharmacologic features of, observations in man on (Grose et al.), 579
Cephalosporin, cefamandole, semisynthetic, observations in man on some pharmacologic features of (Grose et al.), 579
Cerebrospinal fluid concentrations, plasma and, of chlordiazepoxide and its metabolites in surgical patients (Stanski et al.), 571
Chemotherapy, combination, with adriamycin and streptozotocin; clinical results in patients with advanced sarcoma (Chang et al.), 605
clinicopharmacologic correlation of augmented adriamycin toxicity caused by streptozotocin (Chang et al.), 611
Children with chronic asthma, metaproterenol in (Hyde et al.), 207
infants, and adults, pharmacokinetics of succinylcholine in (Cook et al.), 493
loading and conventional dose therapy with phenytoin in; kinetic profile of parent drug and main metabolite in plasma (Wilson et al.), 48
Chlordiazepoxide and its metabolites, plasma and cerebrospinal fluid concentrations of, in surgical patients (Stanski et al.), 571
in man, *N*-desmethyldiazepam, new metabolite of (Dixon et al.), 450

Cholesterol-lowering drug (probucol) effective in patients with type II hyperlipoproteinemia (Salel et al.), 690
Cigarette(s), full-length and half-length, titration of nicotine intake with (Gritz et al.), 552
smoking, effect of; comparison of hydroxylation of zoxazolamine and benzo[a]pyrene in human placenta (Kapitulnik et al.), 557
Cirrhosis, aminopyrine demethylation measured by breath analysis in (Bircher et al.), 484
Clearance calculations, artificial kidneys and (Gibson et al.), 720
Clinical biostatistics. Bailar's laws of data analysis (Bailar), 113
XXXVII. Demeaned errors, confidence games, nonplussed minuses, inefficient coefficients, and other statistical disruptions of scientific communication (Feinstein), 617
and pharmacokinetic observations on hemodialysis for severe procainamide toxicity (Atkinson et al.), 585
pharmacologic observations on atenolol, a beta-adrenoceptor blocker (Brown et al.), 524
pharmacologist and scientifically unsound regulations for drug development (Melmon), 125 (Editorial)
Clonidine, sliding intravenous dose schedule for, in hypertensive patients (Velasco et al.), 31
Cloxacillin, dicloxacillin and: pharmacokinetics in healthy and hemodialysis subjects (Nauta and Mattie), 98
Codeine, aspirin and, in two postpartum pain models (Bloomfield et al.), 499
Coffee and caffeine, dose-related sleep disturbances induced by (Karacan et al.), 682
Colestipol in familial type II hyperlipoproteinemia: three-year trial (Harvengt and Desager), 310
Contraceptives, oral, effect of, on platelet monoamine oxidase, monoamine excretion, and adrenocortical function (Feldman and Roche), 670

D

Demethylation, aminopyrine, measured by breath analysis in cirrhosis (Bircher et al.), 484
Depressed patients treated with nortriptyline, therapeutic response of (Ziegler et al.), 458
Dextroamphetamine-marihuana combination, effects of (Evans et al.), 350
D-Glucaric acid, paradoxical urinary excretion of, in acute viral hepatitis (Sorrell et al.), 365
Dialysis blood or plasma solute concentration, clearance of solutes by artificial kidneys calculated using (Gibson et al.), 720
Dialysis—cont'd
elimination of procainamide and its metabolite markedly accelerated by (Atkinson et al.), 585
Diazepam and bromazepam, blood levels and electroencephalographic effects of (Fink et al.), 184
effect of, on ventilatory responses (Lakshminarayan et al.), 178
Dicloxacillin and cloxacillin: pharmacokinetics in healthy and hemodialysis subjects (Nauta and Mattie), 98
Dietary protein and carbohydrate, effects of, on antipyrine and theophylline metabolism in man (Kappas et al.), 643
Digitalis, studies on; effect of heparin on serum protein binding of digitoxin and digoxin (Storstein), 15
influence of impaired renal function, hemodialysis, and drug interaction on serum protein binding of digitoxin and digoxin (Storstein), 6
of nephrotic syndrome on protein binding, pharmacokinetics, and renal excretion of digitoxin and cardioactive metabolites (Storstein), 158
Digitoxin and cardioactive metabolites, renal excretion of, influence of nephrotic syndrome on protein binding, pharmacokinetics, and; studies on digitalis (Storstein), 158
and digoxin, effect of heparin on serum protein binding of; studies on digitalis (Storstein), 15
influence of impaired renal function, hemodialysis, and drug interaction on serum protein binding of; studies on digitalis (Storstein), 6
Digoxin bioavailability, effect of sulfasalazine on (Juhl et al.), 387
formulations and rates of infusions (Marcus et al.), 253
content, total body, correlation between electrocardiographic changes, serum digoxin, and (Joubert et al.), 676
digitoxin and, effect of heparin on serum protein binding of; studies on digitalis (Storstein), 15
influence of impaired renal function, hemodialysis, and drug interaction on serum protein binding of; studies on digitalis (Storstein), 6
effect of furosemide on renal excretion of (Brown et al), 395
serum, electrocardiographic changes, and total body digoxin content, correlation between (Joubert et al.), 676
transient cardiac arrhythmias after single daily maintenance doses of (Manninen et al.), 266

Diuresis, effect of, in subjects taking digoxin (Brown et al.), 395
Diuretic, new loop, bumetanide (Carrière and Dandavino), 424
Dog and normal man, cardiovascular effects of new inotropic drug in (Follath et al.), 24
Dose calculations, kinetics and, of amikacin in newborn (Sardemann et al.), 59
-related sleep disturbances induced by coffee and caffeine (Karacan et al.), 682
single bedtime, of methyldopa, antihypertensive efficacy of (McLeod et al.), 733
Drug(s), cholesterol-lowering (probucol), effective in patients with type II hyperlipoproteinemia (Salel et al.), 690
development, clinical pharmacologist and scientifically unsound regulations for (Melmon), 125 (Editorial)
discovery and introduction: regulation and overregulation (Lasagna), 507 (Commentary)
effect of renal transplantation on protein binding of, in serum of donor and recipient (Levy et al.), 512
interaction, influence of impaired renal function, hemodialysis, and, on serum protein binding of digitoxin and digoxin; studies on digitalis (Storstein), 6
new anti-inflammatory, analysis of patient volunteers in clinical trial of; "uninformed" consent and wealthy volunteer (Hassar and Weintraub), 379 (Commentary)
inotropic, cardiovascular effects of, in dog and normal man (Follath et al.), 24
oxidation, hepatic, in man, amobarbital, probe of (Inaba et al.), 439

E

Electrocardiographic changes, serum digoxin, and total body digoxin content, correlation between (Joubert et al.), 676
effects of diazepam and bromazepam, blood levels and (Fink et al.), 184
Elliott, Henry Wood, 632 (In memoriam)
Enflurane anesthesia, fluoride kinetics after, in healthy and anephric patients and in patients with poor renal function (Carter et al.), 565
Enzyme induction by oral testosterone (Johnsen et al.), 233
Ethosuximide, metabolism of (Goulet et al.), 213
Etidronate disodium in postmenopausal osteoporosis (Heaney and Saville), 593
Ester, ampicillin and, in experimental *Hemophilus influenzae* meningitis (Bodine et al.), 727

F

Fever, induced, quinine disposition during malaria and, 743 (Correspondence)
Fluoride kinetics after enflurane anesthesia in healthy and anephric patients and in patients with poor renal function (Carter et al.), 565
Food, influence of, on nitrofurantoin bioavailability (Rosenberg and Bates), 227
Furosemide, effect of, on renal excretion of digoxin (Brown et al.), 395
resemblance of bumetanide to (Carrière and Dandavino), 424

G

Gastric and biliary excretion of meperidine in man (Dunkerley et al.), 546
Genetic study of amobarbital elimination based on its kinetics in twins (Endrenyi et al.), 701
Government, therapeutics and: 1776 and 1976 (Abrams), 1 (Commentary)

H

Heart rate, effect of propranolol on (McDevitt et al.), 152
Hemodialysis, impaired renal function, and drug interaction, influence of, on serum protein binding of digitoxin and digoxin; studies on digitalis (Storstein), 6
renal failure, and nafcillin kinetics (Rudnick et al.), 413
for severe procainamide toxicity: clinical and pharmacokinetic observations (Atkinson et al.), 585
subjects, healthy and, pharmacokinetics in: dicloxacillin and cloxacillin (Nauta and Mattie), 98
Hemophilus influenzae meningitis, experimental, ampicillin and ester in (Bodine et al.), 727
Heparin, effect of, on serum protein binding of digitoxin and digoxin; studies on digitalis (Storstein), 15
Hepatic disease, relationship between effects of, on drugs with high and low intrinsic hepatic clearance (Branch et al.), 81
drug oxidation in man, amobarbital, probe of (Inaba et al.), 439
Hepatitis, acute viral, influence of, on disposition and pharmacologic effect of warfarin (Williams et al.), 90
paradoxical urinary excretion of D-glucaric acid in (Sorrell et al.), 365
viral, influence of, on disposition of two compounds with high hepatic clearance: lidocaine and indocyanine green (Williams et al.), 290
Human subjects fed charcoal-broiled beef, enhanced phenacetin metabolism in (Conney et al.), 633

Hydrochlorothiazide, patients with hypertension taking, hypotensive responses to addition of propranolol or oxprenolol (Materson et al.), 142
Hydrocortisone sodium succinate and sodium phosphate, intravenous, anorectal pruritus after (Novak et al.), 109
Hydroxylation of zoxazolamine and benzo[a]pyrene in human placenta, comparison of: effect of cigarette smoking (Kapitulnik et al.), 557
Hyperlipoproteinemia, familial type II, colestipol in: three-year trial (Harvengt et al.), 310
type II, probucol, new cholesterol-lowering drug effective in patients with (Salel et al.), 690
Hypertension, effects of prazosin in patients with (Bolli et al.), 138
essential, plasma levels and effects of metoprolol on blood pressure, adrenergic beta receptor blockade, and plasma renin activity in (von Bahr et al.), 130
patients with, taking hydrochlorothiazide, hypotensive responses to addition of propranolol or oxprenolol (Materson et al.), 142
Hypertensive, anti-, efficacy of single bedtime dose of methyldopa (McLeod et al.), 733
patients, sliding intravenous dose schedule for clonidine in (Velasco et al.), 31

I

Indocyanine green, antipyrine and, clearance of, in normal subjects and in patients with chronic liver disease (Branch et al.), 81
lidocaine and, influence of viral hepatitis on disposition of two compounds with high hepatic clearance (Williams et al.), 290
Infants, children, and adults, pharmacokinetics of succinylcholine in (Cook et al.), 493
Insomnia, sleep laboratory studies on usefulness of Seconal in (Kales et al.), 541
Intestinal blood loss after new anti-inflammatory drug, sulindac (Cohen), 238

K

Kidneys, artificial, and clearance calculations (Gibson et al.), 720
Kinetics, amobarbital, in twins, genetic study of amobarbital elimination based on (Endrenyi et al.), 701
and dose calculations of amikacin in newborn (Sardemann et al.), 59
fluoride, after enflurane anesthesia in healthy and anephric patients and in patients with poor renal function (Carter et al.), 565
plasma, influence of cannabidiol on secobarbital effects and (Dalton et al.), 695

L

Levomethadone and racemic methadone in maintenance program, side effects of (Judson et al.), 445
Lidocaine and indocyanine green: influence of viral hepatitis on disposition of two compounds with high hepatic clearance (Williams et al.), 290
Lithium, changes in serum thyroxine, triiodothyronine, and thyrotropin induced by, in normal subjects and in rats (Child et al.), 715
treatment during alcoholic withdrawal (Sellers et al.), 199
Liver disease, chronic, clearance of antipyrine and indocyanine green in normal subjects and in patients with (Branch et al.), 81
studies on breath, saliva, and urine of normal subjects and patients with, aminopyrine disposition (Hepner and Vesell), 654
Lorazepam, clinical pharmacokinetics of; absorption and disposition of oral ^{14}C-lorazepam (Greenblatt et al.), 329
Lymphocytes, cultured human, elimination of antipyrine and benzo[a]pyrene metabolism in (Kellermann et al.), 72

M

Malaria, quinine disposition during, and during induced fever, 743 (Correspondence)
Man, gastric and biliary excretion of meperidine in (Dunkerley et al.), 546
hepatic drug oxidation in, amobarbital, probe of (Inaba et al.), 439
N-desmethyldiazepam new metabolite of chlordiazepoxide in (Dixon et al.), 450
normal, dog and, cardiovascular effects of new inotropic drug in (Follath et al.), 24
Marihuana-dextroamphetamine combination, effects of (Evans et al.), 350
Meningitis, experimental *Hemophilus influenzae*, ampicillin and ester in (Bodine et al.), 727
Mental and physical stimulation, comparison of effects of (Guazzi et al.), 304
Meperidine, gastric and biliary excretion of, in man (Dunkerley et al.), 546
intramuscular butorphanol and, in postoperative pain (Gilbert et al.), 359
orally administered, systemic availability of (Mather and Tucker), 535
Meprobamate, morphine, pentobarbital, and, subjective and physiologic effects of (McClane and Martin), 192
Metabolism, absorption and, of phenytoin from tablets and capsules (Smith and Kinkel), 738
antipyrine and benzo[a]pyrene, elimination of, in cultured human lymphocytes (Kellermann et al.), 72

Metabolism, antipyrine—cont'd
factors affecting, in West African villagers (Fraser et al.), 369
and theophylline, in man, effects of dietary protein and carbohydrate on (Kappas et al.), 643
disposition, and effects after acute and chronic dosing with naltrexone (Verebey et al.), 315
enhanced phenacetin, in human subjects fed charcoal-broiled beef (Conney et al.), 633
of ethosuximide (Goulet et al.), 213
first-pass, differences in absorption and peak plasma levels of quinidine possibly due to (Ueda et al.), 260
Metabolite(s) of chlordiazepoxide in man, *N*-desmethyldiazepam, new (Dixon et al.), 450
main, in plasma, kinetic profile of parent drug and; loading and conventional dose therapy with phenytoin in children (Wilson et al.), 48
in surgical patients, plasma and cerebrospinal fluid concentrations of chlordiazepoxide and (Stanski et al.), 571
Metaproterenol in children with chronic asthma (Hyde et al.), 207
Methadone, racemic, levomethadone and, side effects of, in maintenance program (Judson et al.), 445
Methyldopa, antihypertensive efficacy of single bedtime dose of (McLeod et al.), 733
Metoprolol, plasma levels and effects of, on blood pressure, adrenergic beta receptor blockade, and plasma renin activity in essential hypertension (von Bahr et al.), 130
Microsomal hemoprotein synthesis not adversely affected in homozygous β-thalassemia (Rifkind et al.), 476
Monoamine excretion, platelet monoamine oxidase, and adrenocortical function, effect of oral contraceptives on (Feldman and Roche), 670
oxidase, platelet, monoamine excretion, and adrenocortical function, effect of oral contraceptives on (Feldman and Roche), 670
Morphine, pentobarbital, and meprobamate, subjective and physiologic effects of (McClane and Martin), 192

N

Nafcillin kinetics, renal failure, hemodialysis, and (Rudnick et al.), 413
Naltrexone: disposition, metabolism, and effects after acute and chronic dosing (Verebey et al.), 315
Naproxen overdoses, pharmacokinetics of (Runkel et al.), 269
Narcotic antagonist action of butorphanol in animals (Gilbert et al.), 359
naltrexone, disposition, metabolism, and effects after acute and chronic dosing (Verebey et al.), 315
N-Desmethyldiazepam: new metabolite of chlordiazepoxide in man (Dixon et al.), 450
Nephrotic syndrome, influence of, on protein binding, pharmacokinetics, and renal excretion of digitoxin and cardioactive metabolites; studies on digitalis (Storstein), 158
Neural depressive effect, lack of evidence for, in antihypertensive action of propranolol in man (Guazzi et al.), 304
Newborn, kinetics and dose calculations of amikacin in (Sardemann et al.), 59
Nicotine intake, titration of, with full-length and half-length cigarettes (Gritz et al.), 552
Nitrofurantoin bioavailability, influence of food on (Rosenberg and Bates), 227
Nomograms for attaining and sustaining desired plasma propranolol levels by intravenous injection (McAllister), 517
Nortriptyline plasma levels and therapeutic response (Ziegler et al.), 458

O

Oral surgery outpatients, model to evaluate mild analgesics in (Cooper and Beaver), 241
Osteoporosis, postmenopausal, etidronate disodium in (Heaney and Saville), 593
Oxidase, platelet monoamine, monoamine excretion, and adrenocortical function, effect of oral contraceptives on (Feldman and Roche), 670
Oxidation, hepatic drug, in man, amobarbital, probe of (Inaba et al.), 439
Oxprenolol, pharmacokinetics of, in normal subjects (Mason and Winer), 401
and propranolol, antihypertensive effects of (Materson et al.), 142

P

Pain models, two postpartum, aspirin and codeine in (Bloomfield et al.), 499
Pentobarbital elimination in patients with poor renal function (Reidenberg et al.), 67
morphine, and meprobamate, subjective and physiologic effects of (McClane and Martin), 192
Pharmacodynamic(s) and pharmacokinetic studies of enantiomers of phenprocoumon (Jähnchen et al.), 342
pharmacokinetics and, of procainamide, relationship between (Galeazzi et al.), 278
Pharmacokinetic(s), clinical, of lorazepam; absorption and disposition of oral ^{14}C-lorazepam (Greenblatt et al.), 329

Pharmacokinetics—cont'd
of dicloxacillin and cloxacillin in healthy and hemodialysis subjects (Nauta and Mattie), 98
of naproxen overdoses (Runkel et al.), 269
observations, clinical and, on hemodialysis for severe procainamide toxicity (Atkinson et al.), 585
of oxprenolol in normal subjects (Mason and Winer), 401
and pharmacodynamics of procainamide, relationship between (Galeazzi et al.), 278
protein binding, and renal excretion of digitoxin and cardioactive metabolites; studies on digitalis (Storstein), 158
studies, pharmacodynamic and, of enantiomers of phenprocoumon (Jähchen et al.), 342
of succinylcholine in infants, children, and adults (Cook et al.), 493
Pharmacologic effect of warfarin, influence of acute viral hepatitis on disposition and (Williams et al.), 90
features, some, of cefamandole, observations in man on (Grose et al.), 579
observations, clinical, on atenolol, beta-adrenoceptor blocker (Brown et al.), 524
Pharmacologist, clinical, and scientifically unsound regulations for drug development (Melmon), 125 (Editorial)
Phenacetin metabolism, enhanced, in human subjects fed charcoal-broiled beef (Conney et al.), 633
Phenprocoumon, enantiomers of: pharmacodynamic and pharmacokinetic studies (Jähnchen et al.), 342
Phenytoin, absorption and metabolism of, from tablets and capsules (Smith and Kinkel), 738
in children, loading and conventional dose therapy with; kinetic profile of parent drug and main metabolite in plasma (Wilson et al.), 48
impaired plasma protein binding of, in uremia and displacement effect of salicylic acid (Odar-Cederlöf and Borgå), 36
Physical stimulation, mental and, comparison of effects of (Guazzi et al.), 304
Physiologic or biochemical change not detected in lithium treatment during alcoholic withdrawal (Sellers et al.), 199
Placenta, human, comparison of hydroxylation of zoxazolamine and benzo[a]pyrene in: effect of cigarette smoking (Kapitulnik et al.), 557
Plasma binding and affinity of propranolol for beta receptor in man (McDevitt et al.), 152
and cerebrospinal fluid concentrations of chlordiazepoxide and its metabolites in surgical patients (Stanski et al.), 571

Plasma—cont'd
flow, clearance of solutes by artificial kidneys calculated by use of (Gibson et al.), 720
half-life of pentobarbital in patients with uremia (Reidenberg et al.), 67
prolonged by administration of antipyrine and aminopyrine (Vesell et al.), 661
kinetic(s), influence of cannabidiol on secobarbital effects and (Dalton et al.), 695
profile of parent drug and main metabolite in; loading and conventional dose therapy with phenytoin in children (Wilson et al.), 48
levels, desired, method for rapidly achieving and sustaining; intravenous propranolol administration (McAllister), 517
and effects of metoprolol on blood pressure, adrenergic beta receptor blockade, and plasma renin activity in essential hypertension (von Bahr et al.), 130
of ethosuximide obtained with single daily doses (Goulet et al.), 213
nortriptyline, and therapeutic response (Ziegler et al.), 458
of phenytoin and urinary throughput, crossover studies conducted to compare (Smith and Kinkel), 738
protein binding, impaired, of phenytoin in uremia and displacement effect of salicylic acid (Odar-Cederlöf and Borgå), 36
and saliva, radioimmunoassay in, following administration of high dose and low dose of antipyrine (Chang et al.), 219
uremic and normal, protein binding of salicylate in (Borgå et al.), 464
from Vacutainers, reduced binding of quinidine in, 120 (Correspondence)
Poisoning, procainamide, renal insufficiency of (Atkinson et al.), 585
Potassium canrenoate, spironolactone and, in normal man (Ransay et al.), 167
Prazosin, effects of, in patients with hypertension (Bolli et al.), 138
Probucol: new cholesterol-lowering drug effective in patients with type II hyperlipoproteinemia (Salel et al.), 690
Procainamide, relationship between pharmacokinetics and pharmacodynamics of (Galeazzi et al.), 278
toxicity, severe, hemodialysis for: clinical and pharmacokinetic observations (Atkinson et al.), 585
Propranolol administration, intravenous: method for rapidly achieving and sustaining desired plasma levels (McAllister), 517
antihypertensive action of, in man: lack of evidence for neural depressive effect (Guazzi et al.), 304
oxprenolol and, antihypertensive effects of (Materson et al.), 142

Propranolol—cont'd
plasma binding and affinity of, for beta receptor in man (McDevitt et al.), 152
Protein binding of drugs in serum of donor and recipient, effect of renal transplantation on (Levy et al.), 512
impaired plasma, of phenytoin in uremia and displacement effect of salicylic acid (Odar-Cederlöf and Borgå), 36
pharmacokinetics, and renal excretion of digitoxin and cardioactive metabolites, influence of nephrotic syndrome on; studies on digitalis (Storstein), 158
of salicylate in uremic and normal plasma (Borgå et al), 464
dietary, and carbohydrate, effects of, on antipyrine and theophylline metabolism in man (Kappas et al.), 643
intrasubject variation of warfarin binding to, in serum of patients with cardiovascular disease (Yacobi et al.), 300
Pruritus, anorectal, after intravenous hydrocortisone sodium succinate and sodium phosphate (Novak et al.), 109

Q

Quinazoline (prazosin) in patients with hypertension (Bolli et al.), 138
Quinidine bioavailability, absolute (Ueda et al.), 260
reduced binding of, in plasma from Vacutainers, 120 (Correspondence)
Quinine disposition during malaria and during induced fever, 743 (Correspondence)

R

Racemic methadone, levomethadone and, side effects of, in maintenance program (Judson et al.), 445
Radioimmunoassay in plasma and saliva following administration of high and low dose of antipyrine (Chang et al.), 219
Rats, changes in serum thyroxine, triiodothyronine, and thyrotropin induced by lithium in normal subjects and (Child et al.), 715
Renal excretion of digitoxin and cardioactive metabolites, influence of nephrotic syndrome on protein binding, pharmacokinetics, and; studies on digitalis (Storstein), 158
of digoxin, effect of furosemide on (Brown et al.), 395
failure, hemodialysis, and nafcillin kinetics (Rudnick et al.), 413
function, impaired, hemodialysis, and drug interaction, influence of, on serum protein binding of digitoxin and digoxin; studies on digitalis (Storstein), 6
Renal function—cont'd
limited, elimination of dicloxacillin reduced in patients with (Nauta and Mattie), 98
poor, patients with, fluoride kinetics after enflurane anesthesia in healthy and anephric patients and (Carter et al.), 565
pentobarbital elimination in patients with (Reidenberg et al.), 67
insufficiency of procainamide poisoning (Atkinson et al.), 585
transplantation, effect of, on protein binding of drugs in serum of donor and recipient (Levy et al.), 512
Renin activity, plasma, plasma levels and effects of metoprolol on blood pressure, adrenergic beta receptor blockade, and, in essential hypertension (von Bahr et al.), 130

S

Salicylate metabolism, correlation of plateau serum salicylate with rate of, 120 (Correspondence)
protein binding of, in uremic and normal plasma (Borgå et al.), 464
Salicylic acid, displacement effect of, impaired plasma protein binding of phenytoin in uremia and (Odar-Cederlöf and Borgå), 36
Saliva, breath, and urine of normal subjects and patients with liver disease, studies on; aminopyrine disposition (Hepner and Vesell), 654
radioimmunoassay in plasma and, following administration of high dose and low dose of antipyrine (Chang et al.), 219
Sarcoma, advanced, clinical results of combination chemotherapy with adriamycin and streptozotocin in patients with (Chang et al.), 605
Secobarbital, effectiveness of intermediate-term use (Kales et al.), 541
effects and plasma kinetics, influence of cannabidiol on (Dalton et al.), 695
Serum calcium increased by etidronate disodium (Heaney and Saville), 593
concentrations, peak, and rates of excretion of digoxin (Marcus et al.), 253
digoxin, electrocardiographic changes, and total body digoxin content, correlation between (Joubert et al.), 676
of donor and recipient, effect of renal transplantation on protein binding of drugs in (Levy et al.), 512
of patients with cardiovascular disease, intrasubject variation of warfarin binding to protein in (Yacobi et al.), 300

Serum—cont'd
phosphorus and serum calcium increased by etidronate disodium (Heaney and Saville), 593
protein binding of digitoxin and digoxin, effect of heparin on; studies on digitalis (Storstein), 15
salicylate, plateau, correlation of, with rate of salicylate metabolism, 120 (Correspondence)
thyroxine, triiodothyronine, and thyrotropin, changes in, induced by lithium in normal subjects and in rats (Child et al.), 715
Sleep disturbances, dose-related, induced by coffee and caffeine (Karacan et al.), 682
laboratory studies on usefulness of Seconal in insomnia (Kales et al.), 541
Smoking, cigarette, effect of; comparison of hydroxylation of zoxazolamine and benzo[a]pyrene in human placenta (Kapitulnik et al.), 557
Sodium phosphate, intravenous hydrocortisone sodium succinate and, anorectal pruritus after (Novak et al.), 109
succinate and sodium phosphate, intravenous hydrocortisone, anorectal pruritus after (Novak et al.), 109
Spironolactone and potassium canrenoate in normal man (Ramsay et al.), 167
Statistical disruptions of scientific communication; clinical biostatistics (Feinstein), 617
Streptozotocin, adriamycin and, combination chemotherapy with; clinical results in patients with advanced sarcoma (Chang et al.), 605
clinicopharmacologic correlation of augmented adriamycin toxicity caused by streptozotocin (Chang et al.), 611
Succinylcholine, pharmacokinetics of, in infants, children, and adults (Cook et al.), 493
Sulfasalazine, effect of, on digoxin bioavailability (Juhl et al.), 387
Sulindac, new anti-inflammatory drug, intestinal blood loss after (Cohen), 238
Surgery, oral, outpatients, model to evaluate mild analgesics in (Cooper and Beaver), 241
Surgical patients, plasma and cerebrospinal fluid concentrations of chlordiazepoxide and its metabolites in (Stanski et al.), 571
Systemic availability of orally administered meperidine (Mather and Tucker), 535

T

Testosterone, oral, enzyme induction by (Johnsen et al.), 233
Theophylline metabolism, antipyrine and, in man, effects of dietary protein and carbohydrate on (Kappas et al.), 643
Therapeutics and government: 1776 and 1976 (Abrams), 1 (Commentary)
Thyrotropin, changes in serum thyroxine, triiodothyronine, and, induced by lithium in normal subjects and in rats (Child et al.), 715
Thyroxine, serum, triiodothyronine, and thyrotropin, changes in, induced by lithium in normal subjects and in rats (Child et al.), 715
Titration of nicotine intake with full-length and half-length cigarettes (Gritz et al.), 552
Toxicity, augmented adriamycin, caused by streptozotocin, clinicopharmacologic correlation of (Chang et al.), 611
severe procainamide, hemodialysis for: clinical and pharmacokinetic observations (Atkinson et al.), 585
Transplantation, renal, effect of, on protein binding of drugs in serum of donor and recipient (Levy et al.), 512
Trial, clinical, of new anti-inflammatory drug, analysis of patient volunteers in; "uninformed" consent and wealthy volunteer (Hassar and Weintraub), 379 (Commentary)
Triiodothyronine, thyroxine, and thyrotropin, serum, changes in, induced by lithium in normal subjects and in rats (Child et al.), 715
Twins, genetic study of amobarbital elimination based on its kinetics in (Endrenyi et al.), 701

U

Uremia, impaired plasma protein binding of phenytoin in, and displacement effect of salicylic acid (Odar-Cederlöf and Borgå), 36
shorter plasma half-life of pentobarbital in patients with (Reidenberg et al.), 67
Uremic and normal plasma, protein binding of salicylate in (Borgå et al.), 464
Urinary excretion, paradoxical, of D-glucaric acid in acute viral hepatitis (Sorrell et al.), 365
throughput, crossover studies conducted to compare plasma levels of phenytoin and (Smith and Kinkel), 738
Urine, breath, saliva, and, of normal subjects and patients with liver disease, studies on; aminopyrine disposition (Hepner and Vesell), 654

V

Vacutainers, reduced binding of quinidine in plasma from, 120 (Correspondence)
Ventilatory responses, effect of diazepam on (Lakshminarayan et al.), 178

Viral hepatitis, acute, influence of, on disposition and pharmacologic effect of warfarin (Williams et al.), 90
paradoxical urinary excretion of D-glucaric acid in (Sorrell et al.), 365
influence of, on disposition of two compounds with high hepatic clearance: lidocaine and indocyanine green (Williams et al.), 290
Volunteer, wealthy, "uninformed" consent and: analysis of patient volunteers in clinical trial of new anti-inflammatory drug (Hassar and Weintraub), 379 (Commentary)

W

Warfarin binding to protein, intrasubject variation of, in serum of patients with cardiovascular disease (Yacobi et al.), 300
Warfarin—cont'd
influence of acute viral hepatitis on disposition and pharmacologic effect of (Williams et al.), 90
West African villagers, factors affecting antipyrine metabolism in (Fraser et al.), 369

Z

Zoxazolamine and benzo[a]pyrene in human placenta, comparison of hydroxylation of: effect of cigarette smoking (Kapitulnik et al.), 557